Experimental mRNA cancer vaccine cuts risk of melanoma returning by 42%: ‘A new frontier'

An experimental mRNA cancer vaccine from Moderna has reduced the risk of melanoma returning by 42%. This breakthrough highlights the versatility of mRNA technology beyond Covid, as Moderna also awaits US regulatory approval for an RSV shot. This advancement represents a new frontier in medicine, with scientists now studying similar mRNA vaccines to treat other conditions, including glioblastoma and pancreatic cancer, aiming to effectively prevent and treat a wider range of illnesses.